Rxsight, Inc. Stock Price, News & Analysis

Biobeat Technologies has appointed Raymond W. Cohen as Chairman of the Board of Directors. The company, which develops wearable medical devices, has received FDA clearance for its innovative patch device that monitors multiple physiological parameters including continuous cuff-less ambulatory blood pressure.

Cohen brings over 40 years of life science industry experience, notably as co-founder and CEO of Axonics, which was acquired by Boston Scientific for $3.7 billion in 2024. Under his leadership, Axonics generated over $1 billion in revenue within four years of commercial launch. Most recently, as chairman of SoniVie, he led its sale to Boston Scientific for $600 million in March 2025.

RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The company's management will deliver their presentation on September 4, 2025, at 10:15 AM ET. Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.rxsight.com.

RxSight (NASDAQ:RXST), an ophthalmic medical device company, reported mixed Q2 2025 financial results. Revenue decreased 4% year-over-year to $33.6 million, despite a 13% increase in Light Adjustable Lens (LAL) procedure volume to 27,380 units. The company's Light Delivery Device (LDD) installed base grew 34% to 1,084 units, though LDD sales declined 49% year-over-year.

The company reported a net loss of $(0.29) per share, compared to $(0.16) in Q2 2024. Gross margin improved to 74.9% from 69.5%. Notable developments include FDA approval for expanded LAL dioptric power range, launches in South Korea and Singapore, and a commercial organization realignment. RxSight maintained its full-year 2025 guidance of $120-130 million in revenue.

RxSight (Nasdaq: RXST), a medical device company specializing in customized vision solutions for cataract surgery patients, has appointed Raymond W. Cohen to its Board of Directors. Cohen, a seasoned medical technology executive with over 40 years of experience, notably led Axonics Inc. to generate over $1 billion in revenue within four years before its $3.7 billion acquisition by Boston Scientific in 2024.

As chairman of SoniVie Ltd., Cohen recently orchestrated its $600 million sale to Boston Scientific in March 2025. He currently serves on multiple healthcare company boards and brings extensive experience in scaling medical technology companies. Cohen expressed confidence in helping RxSight strengthen its position in the premium intraocular lens market and accelerate revenue and profit growth.

RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on customized vision solutions for post-cataract surgery patients, has scheduled its Q2 2025 financial results announcement for August 7, 2025, after market close.

The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss the results. Investors can join via phone using the numbers (800) 715-9871 or (646) 307-1963 with conference code 633359, or listen to the webcast through the company's investor relations website.

RxSight (NASDAQ: RXST), an ophthalmic medical device company, reported disappointing preliminary Q2 2025 results and significantly lowered its full-year guidance. Revenue is expected to be $33.6 million, down 4% year-over-year and 11% sequentially.

The company sold 27,380 Light Adjustable Lenses (up 13% YoY but down 1% QoQ) and 40 Light Delivery Devices (down 49% YoY and 45% QoQ). The installed base grew 34% YoY to 1,084 LDDs.

RxSight revised its 2025 guidance downward, now expecting revenue of $120-130 million (previously $160-175 million), while increasing gross margin guidance to 72-74% and reducing operating expense projections to $145-155 million.

RxSight, Inc. (NASDAQ: RXST), a company specializing in ophthalmic medical devices for post-cataract surgery vision customization, has announced its participation in the upcoming Stifel Virtual Ophthalmology Forum. The company's management team will engage in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties can access both the live and archived versions of the presentation through RxSight's investor relations website at investors.rxsight.com.

RxSight (RXST) reported strong Q1 2025 financial results with revenue of $37.9 million, up 28% year-over-year. The company sold 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedures, and added 73 Light Delivery Devices (LDD™s), expanding the installed base to 1,044 units. Gross profit reached $28.3 million (74.8% margin), while net loss improved to $(8.2) million or $(0.20) per share. The company maintained its 2025 guidance, projecting revenue of $160-175 million and operating expenses of $150-160 million. Management highlighted strong customer enthusiasm and strategic growth opportunities through service center expansion and international approvals.

RxSight, a specialized ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Bank of America Healthcare Conference in Las Vegas.

The company's management team is set to deliver their presentation on Wednesday, May 14, 2025, at 3:40 PM Pacific Time (6:40 PM Eastern Time). Investors and interested parties can access both the live presentation and archived recording through the company's investor relations website at https://investors.rxsight.com/.

This presentation at a major healthcare conference represents an opportunity for RxSight to showcase their innovations in customized vision solutions for cataract surgery patients. The company's participation in this significant industry event demonstrates their commitment to engaging with the investment community and sharing their business developments.